Abstrakt

Association between Diabetes Type 2 and Cardiovascular Diseases and the Role of SGLT2 Inhibitors

Dr. Mohammad Reza Shoghli

 The number of people who die from kidney disease every year has risen over the past decade and is now estimated at 5 million to 10 million worldwide. The increase in rates of obesity along with associated rates of type 2 diabetes, hypertension, and cardiovascular disease has principally driven the elevated mortality. More than 660,000 Americans have reached the point of requiring intervention for end-stage kidney disease, with 468,000 receiving dialysis and more than 193,000 undergoing kidney transplantation, leading to a major public health and economic burden. Hence, the development of new treatments that may prevent or delay the progression of chronic kidney disease, as well as treat type 2 diabetes, is an important goal. Tight control of glucose levels and blood pressure slows but does not prevent the onset of diabetic nephropathy. The standard approach for retarding the onset of diabetic nephropathy and stabilizing renal function has been blockade of the renin–angiotensin–aldosterone system, particularly with inhibitors of angiotensin-converting enzyme.